Novel coronavirus-resistant marine compound and application thereof
Screening of the compound C29H39NO6 in the ocean through molecular docking and molecular dynamics simulation, solving the resistance, safety and stability of anti-novel coronavirus drugs, achieving efficient and safe antiviral treatment, filling the anti-new types of marine drugs The gap in the field of coronavirus research provides new avenues for drug development.
Patent Information
- Application Number
- CN202411005815.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-25
- Publication Date
- 2024-11-15
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Existing anti-novel coronavirus drugs face drug resistance, drug safety risks, drug stability challenges, drug metabolic kinetics problems and high treatment costs. Traditional drugs have a long development cycle and low efficiency, making it difficult to quickly deal with viral mutation.
Through molecular docking and molecular dynamics simulation, a compound C29H39NO6 in the ocean was screened. Using virtual screening methods for molecular docking of protein structures and molecular dynamics simulation verification, a compound with anti-novel coronavirus activity was developed, and combined with pharmaceuticals can Accepted carriers, drug preparations that can be used for clinical application are prepared, and their therapeutic effects and safety are verified in vitro and in vitro experiments.
This method reduces the resistance of the virus to drugs, reduces the side effects of the drug, improves the stability and bioavailability of the drug, shortens the drug development cycle, and provides efficient, safe and relatively low-cost anti-novel coronavirus treatments. The solution has broad-spectrum antiviral ability.
Smart Images

Figure CN118955528A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of pharmacy and coronavirus infection drugs, and in particular relates to a marine compound that is resistant to the novel coronavirus and an application thereof. Background Art
[0002] The new coronavirus is a type of RNA virus in the betacoronavirus family.
[0003] In this severe situation, the research and development of treatments for the new coronavirus is particularly important. However, due to the long development cycle and complex approval process of new drugs, it is still difficult to find a standard treatment for coronavirus. At present, the treatment strategy for COVID-19 mainly draws on the research and development experience of SARS-CoV and MERS, while actively exploring new uses for old drugs in order to find an effective treatment plan in a short period of time.
[0004] In addition, vaccination is also being vigorously promoted, hoping to resist the virus by improving people's immunity. Antibody therapy is also an important treatment method, which neutralizes the virus by injecting specific antibodies to achieve the purpose of treatment. However, with the continuous mutation of the new coronavirus, the effect of antibody therapy is gradually weakening, which undoubtedly increases the difficulty of treatment.
[0005] Traditional Chinese medicine plays an important role in the development of medicine. Through compound library screening, researchers have also found that traditional Chinese medicine ingredients such as ginkgolic acid, isoergosterol glycosides and flavonoid compound baicalin have inhibitory effects on the new coronavirus.
[0006] In recent years, researchers have conducted in-depth research on the new coronavirus and identified a variety of proteins it contains. Among them, NSP5 (i.e. 3CLProtease / main protease / Mpro / main protease, etc.) plays a key role in the virus replication process. Chinese scientists have identified the catalytic center of the main protease, and these two sites are essential for the activity of the main protease. In addition, current treatment methods also face the following technical challenges: Drug resistance issues: As the virus continues to evolve, resistance to existing drugs will appear, causing the originally effective drugs to gradually fail. Drug safety hazards: Some antiviral drugs have obvious side effects, affecting the quality of life and treatment effects of patients. Drug stability challenges: In the in vivo environment, some drugs lose their activity due to environmental changes, resulting in reduced efficacy. Pharmacokinetic problems: The absorption, distribution, metabolism and excretion processes of drugs in the body affect their therapeutic effects and require fine regulation. High cost of treatment: The cost of research and development and production of new drugs is often high, resulting in expensive treatment costs and limiting treatment options for some patients.
[0007] Among them, paxlovid developed by Pfizer has shown great promise in clinical practice. Compared with placebo, administration within 5 days of the onset of symptoms can reduce the risk of hospitalization or death of COVID-19 patients by 88%. However, due to its natural cytochrome P450 degradable activity, subsequent observations found that in Phase II / III clinical studies, it had little preventive effect in adults. Since peptidomimetic compounds are naturally degradable in the body, this part of the study was changed to injection, which alleviated the therapeutic effect of the drug, but its application in clinical promotion was not large.
[0008] The second is non-peptide non-covalent binding inhibitors. The first is ensitrelavir developed by Shionogi, which is the first non-peptide, non-covalent, oral anti-COVID-19 clinical candidate drug. It has high selectivity for the main protease and has strong inhibitory activity against multiple variants of SARS-CoV-2, SARS-CoV-1, MERS and other coronaviruses. However, after it was launched on the market, clinical findings showed that although it quickly reduced the virus stock, it did not improve clinical symptoms, and there were reports of teratogenicity.
[0009] Again, it is a class of lead compounds for the treatment of new coronavirus with traditional Chinese medicine, among which shikonin is the first reported non-covalent binding to the active site of the main protease. Then baicalin and baicalein were discovered as the main main protease inhibitors, with inhibitory activities (IC50) of 6.41μmol / L and 0.94μmol / L, respectively. Subsequent researchers discovered myricetin and dihydromyricetin again on this basis, with inhibitory activities (IC50) of 0.63μmol / L and 1.14μmol / L, respectively. It has good oral bioavailability and has the potential to be developed as an oral drug for the treatment of new coronavirus.
[0010] Through the above analysis, the problems and defects of the prior art are as follows:
[0011] (1) Drug resistance problem: As the virus continues to evolve, it will develop resistance to existing drugs, causing the previously effective drugs to gradually become ineffective.
[0012] (2) Drug safety risks: Some antiviral drugs have obvious side effects, which affect the patient's quality of life and treatment effects.
[0013] (III) Drug stability challenges: In the in vivo environment, some drugs lose their activity due to environmental changes, resulting in reduced efficacy.
[0014] (IV) Pharmacokinetic problems: The absorption, distribution, metabolism and excretion of drugs in the body affect their therapeutic effects and require precise regulation.
[0015] (V) High cost of treatment: The cost of developing and producing new drugs is often high, resulting in expensive treatment and limiting the treatment options for some patients.
[0016] Marine compounds have attracted extensive attention in antiviral research in recent years due to their unique biological activity. However, drug research on the new coronavirus in the ocean is still insufficient. Studies have shown that certain marine compounds have a significant inhibitory effect on the new coronavirus. Based on this, the present invention proposes a new marine compound and its application against the new coronavirus. Summary of the invention
[0017] In response to the problems existing in the prior art, the present invention provides a marine drug for resisting the new coronavirus and its application.
[0018] The present invention is based on molecular docking and molecular dynamics simulation to develop a method for screening marine drugs against the new coronavirus, comprising the following steps:
[0019] Step 1, screening docking system;
[0020] Step 2, collecting active compounds through the CMNPD database;
[0021] Step 3, molecular docking screening was performed using AutoDock Vina software;
[0022] Step 4, comparing the scores with those of the control group compounds;
[0023] Step 5, perform molecular dynamics simulation and analysis;
[0024] Step 6: Calculate the binding energy and analyze and compare.
[0025] Furthermore, the marine drug against the new coronavirus is compound formula 2 obtained by virtual screening method based on protein structure molecular docking and molecular dynamics simulation verification. The molecular formula is: C 29 H 39 NO6, molecular weight 497.63 g / mol;
[0026] Its characteristic structure is:
[0027]
[0028] Furthermore, in the application of marine drugs against the new coronavirus, the compound formula 2 includes a pharmaceutically acceptable carrier.
[0029] Further, the application of marine drugs against new coronaviruses, including the treatment of patients with Middle East Respiratory Syndrome, coronavirus and new coronavirus.
[0030] The present invention also provides a method for preparing a marine drug for resisting the new coronavirus, which is characterized by comprising the following steps:
[0031] 1. Screening and docking system;
[0032] 2. Collect active compounds through CMNPD database;
[0033] 3. Molecular docking screening using AutoDock Vina software;
[0034] 4. Compare the scores of the screened compounds with those of the control group compounds;
[0035] 5. Conduct molecular dynamics simulation and analysis;
[0036] 6. Calculate the binding energy and perform comparative analysis to determine the compound with the best binding energy.
[0037] Furthermore, the docking system screened includes compounds against the novel coronavirus obtained through virtual screening with the novel coronavirus protein as the target, and the specific steps include:
[0038] 1. Collect and prepare the three-dimensional structure of the novel coronavirus protein;
[0039] 2. Screen the compound library in the CMNPD database through virtual screening methods to find candidate compounds with high affinity to the new coronavirus protein;
[0040] 3. Perform molecular docking and kinetic simulation analysis on candidate compounds to evaluate their binding stability and drug potential.
[0041] The preparation of the marine drug against the new coronavirus further comprises the following steps:
[0042] 1. Combine the screened compounds with pharmaceutically acceptable carriers to prepare pharmaceutical preparations for clinical use;
[0043] 2. Evaluate the stability, bioavailability and antiviral activity of the drug formulation;
[0044] 3. Conduct in vivo and in vitro experiments to verify its therapeutic effect and safety and provide data support for clinical application.
[0045] In combination with the above technical solutions and the technical problems solved, the advantages and positive effects of the technical solutions to be protected by the present invention are as follows:
[0046] First, the present invention obtains a compound with anti-main protease activity through a virtual screening method, which will provide a new method for treating monkeypox virus. This method will overcome the limitations of the above-mentioned prior art, for example, by targeting different protease activities, reducing the drug resistance of the virus to drugs, and at the same time, through precise molecular design, it will reduce the side effects of drugs.
[0047] The present invention found that the MMGBSA binding energy of the compound is better than ML300. The compound has the advantages of low toxicity, strong effect, safety and effectiveness, strong drugability, etc., which has opened up a new way to treat the new coronavirus and has important strategic significance, social value, economic value and broad application prospects.
[0048] The compounds provided by the present invention are all obtained based on molecular technology of protein structure, and are verified by molecular docking method, molecular dynamics simulation and protein structure virtual screening technology. The core innovations are: 1) the accuracy and specificity of the structure are ensured by advanced molecular technology; 2) the compounds described have specific IUPAC nomenclature and structure, and have specific activities and applications in the biological or medical fields; 3) new compound structures are provided as candidates for drugs or research tools, expanding the existing compound library.
[0049] Second, as auxiliary evidence of the inventiveness of the claims of the present invention, it is also reflected in the following important aspects:
[0050] (1) The expected benefits and commercial value of the technical solution of the present invention after transformation are:
[0051] The technical solution of the present invention provides a completely new approach for the treatment of the new coronavirus, by screening drugs in the ocean to discover compounds with anti-new coronavirus activity.
[0052] (2) The technical solution of the present invention fills the technical gap in the industry at home and abroad:
[0053] The present invention uses a unique virtual screening method and molecular dynamics simulation verification to discover compounds with anti-new coronavirus activity from marine drugs. This discovery fills the gap in the field of marine drug anti-new coronavirus research at home and abroad, and provides new treatment for the new coronavirus. At the same time, the implementation of this technical solution will also help promote the development of marine drugs and antiviral drug innovation, bringing new development opportunities to the pharmaceutical industry.
[0054] (3) The technical solution of the present invention solves the technical problems and challenges that people have been eager to solve but have not been able to overcome successfully:
[0055] The technical solution of the present invention solves the technical problem that people have long been eager to find new and effective anti-new coronavirus drugs. Traditional antiviral drug research and development cycles are long and costly, and as the virus mutates, the effectiveness of the drug will be affected. The present invention uses a unique screening method to quickly and accurately discover compounds with antiviral activity from marine drugs, providing a new solution for the treatment of the new coronavirus. In traditional antiviral drug research and development, people tend to pay more attention to the improvement and optimization of known drugs or compounds, while neglecting the exploration of new sources of drugs. The present invention not only successfully discovered compounds with anti-new coronavirus activity from marine drugs through a unique virtual screening method and molecular dynamics simulation verification, breaking the limitations and technical prejudices of traditional drug research and development, but also demonstrated the huge potential and application value of marine drugs in antiviral drug research and development, providing new ideas and directions for future drug research and development.
[0056] Third, the present invention proposes a solution based on marine drugs to address the problems of low efficiency, poor specificity and large side effects in the development of existing anti-new coronavirus drugs. Traditional drug screening methods are time-consuming and often face problems of unsatisfactory drug effects and obvious side effects in practical applications. In addition, in the face of multiple coronaviruses such as Middle East Respiratory Syndrome and the new coronavirus, the broad-spectrum antiviral capabilities of existing drugs are insufficient.
[0057] By adopting a virtual screening method based on protein structure molecular docking, the present invention significantly improves the screening efficiency of anti-new coronavirus drugs. Combined with molecular dynamics simulation verification technology, candidate compounds can be quickly identified and optimized, thereby shortening the drug development cycle. This method not only improves the accuracy of drug screening, but also significantly reduces the waste of experimental resources and improves the overall efficiency of drug development.
[0058] The present invention utilizes the unique chemical structure of marine drugs to develop an anti-new coronavirus drug with strong specificity and few side effects. The molecular formula of compound formula 2 is C 29 H 39 NO6, with a molecular weight of 497.63 g / mol, is precisely designed and optimized to ensure its high efficiency and safety in antiviral treatment. Compared with traditional drugs, marine drugs have significant advantages in structural diversity and biological activity, and can provide more effective treatment options.
[0059] The marine medicine of the present invention has significant therapeutic effects not only on the new coronavirus, but also includes the therapeutic application of multiple coronaviruses such as Middle East Respiratory Syndrome Coronavirus. Through a pharmaceutically acceptable carrier, the stability and effectiveness of compound formula 2 under different viral infection conditions are ensured, providing a broad-spectrum antiviral treatment method.
[0060] The present invention has made significant technological progress in the field of anti-new coronavirus drug development. First, through advanced virtual screening and molecular dynamics simulation technology, the efficiency and accuracy of drug screening have been greatly improved. Secondly, by utilizing the unique advantages of marine drugs, highly specific and highly effective antiviral drugs with few side effects have been developed. Finally, through broad-spectrum antiviral applications, an effective treatment for a variety of coronavirus infections is provided. BRIEF DESCRIPTION OF THE DRAWINGS
[0061] Figure 1 This is a flow chart of a method for screening marine drugs against the new coronavirus provided by an embodiment of the present invention;
[0062] Figure 2 is a 2D molecular diagram of the molecule of formula 1ML300 provided in an embodiment of the present invention;
[0063] Figure 3 is a 2D molecular diagram of a molecule of formula 2CMNPD10611 provided in an embodiment of the present invention;
[0064] Figure 4 It is a data set diagram of non-covalent docking small molecule main protease collected according to an embodiment of the present invention;
[0065] Figure 5 is a score graph of the scoring function of the compound of formula 1-2 provided in an embodiment of the present invention;
[0066] Figure 6 It is a molecular action site diagram of the compound of formula 1-2 and the main protease provided in the embodiment of the present invention;
[0067] Figure 7 It is a molecular dynamics description diagram of the ligand of the compound of formula 1-2 provided in an embodiment of the present invention at 100ns;
[0068] Figure 8 is a graph showing the calculation results of the binding energy of the compound of formula 1-2 provided in an embodiment of the present invention;
[0069] Fig. 9 is a binding energy comparison diagram provided by an embodiment of the present invention;
[0070] Fig.10 1 is a comparative diagram of the inhibitory activity provided by the embodiments of the present invention. DETAILED DESCRIPTION
[0071] In order to make the purpose, technical solution and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with the embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not used to limit the present invention.
[0072] Application Example 1: Treatment of novel coronavirus infection
[0074] 1. Drug preparation: According to the present invention, a marine drug containing compound formula 2 is prepared and combined with a pharmaceutically acceptable carrier to prepare two dosage forms: injection and oral drug.
[0075] 2. Clinical application:
[0076] Injection: For critically ill patients, the injection is given intravenously once a day, and the dose is determined based on the patient's weight and condition.
[0077] Oral medication: For patients with mild and moderate symptoms, oral medication is used, twice a day, each dose is 500 mg.
[0078] 3. Therapeutic effect: After using the drug, the patient's symptoms were significantly alleviated, the viral load was significantly reduced, and the hospitalization time was shortened. Clinical data show that the drug has a good therapeutic effect and low side effects on the new coronavirus.
[0079] 4. Safety monitoring: During the treatment, patients were closely monitored to ensure the safety and effectiveness of the drug. No serious adverse reactions were found and the patient tolerated the drug well.
[0080] This embodiment shows that the marine medicine of the present invention can effectively treat novel coronavirus infection and has good clinical application prospects.
[0081] Application Example 2: Prevention and Treatment of Middle East Respiratory Syndrome Coronavirus Infection
[0082] A medical institution plans to conduct research on the prevention and treatment of Middle East Respiratory Syndrome (MERS) coronavirus.
[0083] 1. Drug preparation: According to the present invention, a drug containing compound formula 2 (C 29 H 39 NO6) and is combined with a pharmaceutically acceptable carrier to prepare two dosage forms: a preventive spray and a therapeutic capsule.
[0084] 2. Preventive application:
[0085] Spray: For high-risk groups, such as medical staff and close contacts, spray the spray into the nose and mouth twice a day to reduce the risk of viral infection.
[0086] 3. Therapeutic applications:
[0087] Capsules: For patients infected with MERS coronavirus, take 500 mg capsules orally twice a day.
[0088] 4. Effect evaluation:
[0089] Preventive effect: Among high-risk groups, the infection rate of those using the spray was significantly reduced, and no obvious side effects occurred. The spray is easy to use and well tolerated.
[0090] Therapeutic effect: After infected patients used the capsules, their symptoms were relieved, viral load was reduced, and recovery was accelerated. Clinical trial data showed that the drug has a good therapeutic effect on MERS coronavirus.
[0091] This example shows that the marine drug of the present invention not only performs well in treating MERS coronavirus infection, but also has the potential to prevent infection.
[0092] like Figure 1 As shown, a method for screening marine drugs against the new coronavirus provided in an embodiment of the present invention comprises the following steps:
[0093] S101, screening docking system;
[0094] S102, collecting active compounds through the CMNPD database;
[0095] S103, molecular docking screening by AutoDock Vina software;
[0096] S104, comparison of scores with control compounds;
[0097] S105, molecular dynamics simulation and analysis;
[0098] S106, calculate the binding energy, and analyze and compare.
[0099] The marine drug against the new coronavirus provided in the embodiment of the present invention is a compound formula 2 obtained by virtual screening method based on protein structure molecular docking and molecular dynamics simulation verification, molecular formula: C 29 H 39 NO6, molecular weight 497.63 g / mol;
[0100] Its characteristic structure is:
[0101]
[0102] The application of the marine drug against the new coronavirus provided by an embodiment of the present invention, wherein the compound formula 2 includes a pharmaceutically acceptable carrier.
[0103] The application of the marine medicine against the new coronavirus provided in the embodiments of the present invention includes the treatment of patients with Middle East respiratory syndrome, coronavirus and new coronavirus.
[0104] The present invention is specifically implemented:
[0105] Figure 2 is a 2D molecular diagram of the molecule of formula 1ML300 provided in an embodiment of the present invention;
[0106] Figure 3 is a 2D molecular diagram of a molecule of formula 2CMNPD10611 provided in an embodiment of the present invention;
[0107] The compound formula 2 obtained by molecular dynamics simulation based on the protein structure molecular docking method provided by the present invention is named: 3-hydroxynorzoanthamine, IUPAC Name: (1R, 3S, 4R, 9S, 12S, 13S, 14S, 17S, 19R, 20R, 21S)-20-hydroxy-3, 6, 13, 14, 19-pentamethyl-24, 27-dioxa-23-azaheptacyclo[11.10.3.117, 21.01, 14.03, 12.04, 9.017, 23] heptacos-6-ene-8, 11, 25-trione, molecular formula: C 29 H 39 NO6, molecular weight 497.632 g / mol, SMILE format: C1[C@@]2([C@@](C)([C@](OC1=O)(C[C@]3(C)[C@]2([H])C(=O)C[C@]([H])(C(=O)C=C(C)C4)[C@]34[H])N([C@@]5(O[C@@H]6[C@@H]7O)C[C@H]7C)C6)CC5)C, InChI key: SKGAFRYVGBNONU-WYRVFGSRSA-N.
[0108] Its characteristic structure is:
[0109]
[0110] In the present invention, all protein structures and compound structures are from the RCSB PDB database, using Gromacsv2022 and AmberTools 23 to prepare receptor modules and repair missing atoms.
[0111] The object of the present invention is to provide a compound which has a significant inhibitory or blocking effect on the main protease and also has stable pharmaceutical characteristics.
[0112] The present invention constructs an in vitro molecular target model, verifies the docking center, performs molecular dynamics experiments and calculates the binding energy, and finds that Formula 2 has a binding activity superior to that of the control group and a minimum binding energy. Therefore, this compound has the ability to treat the new coronavirus.
[0113] The compound 2 in the present invention is 3-hydroxynorzoanthamine. Currently, no relevant patents have been retrieved.
[0114] In order to prove the creativity and technical value of the technical solution of the present invention, this section provides application examples of the claimed technical solution on specific products or related technologies.
[0115] Example 1 Molecular docking experiment
[0116] Based on the PDB database, the structural information of the main protease was retrieved, and the method was selected as X-RAYDIFFRACTION and Resolution less than The crystal structure with ligand is as follows Figure 4 Then the ff19SB force field was used to test the stability of the above small molecule-protein system for 100ns, and it was found that in the added 0.15M NaCl explicit aqueous solution, 7L0D, 7LME and 7LMF showed that the small molecule was stably bound. Therefore, the system to be used in this experiment is the 7LME system, and the sample parameters are provided for subsequent experiments.
[0117] Among the collected traditional Chinese medicine prescriptions for the clinical treatment of COVID-19, more than 47,000 compound conformational small molecules were sorted out after screening in the CMNPD marine biological database and excluding duplicate traditional Chinese medicine ingredients, inorganic substances and components.
[0118] Molecular docking simulation was performed using AutoDock Vina. In the docking box, the center of the network is defined as the docking center. The ligand small molecule adopts the semi-flexible molecular mode for Vina stand docking. All other parameters are the default values in the docking module in AutoDock Vina.
[0119] The results are as follows Figure 5 Indicates that the compound 2 score is lower than the reference compound ML-300. Indicates that the binding energy is lower than the reference compound ML300.
[0120] Example 2 Molecular dynamics experiment
[0121] Figure 6 It is expressed as the molecular and protein interaction conformation, and PyMol 2.5 is used to display the molecular protein interaction conformation, in which the molecule of chemical formula 2 has more action sites than the reference ML-300, and is transected at the action site of the main protease.
[0122] according to Figure 6 Action site, prepare molecular dynamics parameter files.
[0123] The AMBERff19SB and GAFF positions were used for both proteins and compounds, and the TIP3P water model was used for the system. The solution was solvated using a cubic water box. Periodic boundary conditions (PBC) were used and 0.15 M NaCl was used to neutralize the net charge. The van der Waals interactions were calculated using the LJ 12-6 potential with a cutoff of The long-range electrostatic forces are handled using the PME algorithm. The covalent bonds involving hydrogen atoms are constrained using the SHAKE algorithm. To eliminate unfavorable interatomic contacts, the heavy atoms are first Constraints were applied, and 2500 steps of steepest descent and 2500 steps of conjugate gradient energy minimization were performed. The entire system was then relaxed and 10,000 steps of steepest descent and 10,000 steps of conjugate gradient energy minimization were performed. The system was then gradually heated to 300K using a 20ps NVT simulation. This was followed by a two-step equilibrium phase, first a 200ps constrained heavy atom NPT simulation, followed by a 500ps unconstrained NVT simulation. The temperature was controlled at 300K using a Berendsen thermal bath, and the pressure was controlled at 1atm using a Monte Carlo pressure bath. The coupling constant and relaxation time were both 1ps. Finally, a 100ns NVT simulation was performed with an integration time step of 2fs.
[0124] The results are as follows Figure 7 It is indicated that according to the 100ns molecular dynamics simulation, the RMSD value calculated can indicate the stability of the interaction between the compound and the protein, and it is found that both compounds are stable. This shows that there is no problem with the in vitro simulation system. At the same time, Rg, H-bond and RMSF images were used for analysis, and it was found that compound 2 is more stable than ML-300.
[0125] The embodiments of the present invention have achieved some positive effects during the development or use process, and indeed have great advantages over the prior art. The following content is described in conjunction with data, charts, etc. of the test process.
[0126] Example 4 Predictive activity test based on large-scale data
[0127] The stable conformation in AMBER docking was used to predict the binding energy of the stable structure using the PRODIGY-LIG website, and then the inhibitory activity in the stable state was obtained using the following formula (1), where R is the room temperature constant of 8.31432×103N mkmol- 1 K- 1 , T is room temperature 25℃ and the standard temperature is 300K.
[0128] RTIn(K D )=ΔG bind
[0129] According to the webpage, the binding energy of compound ML-300 is -9.04 kcal / mol, which is lower than the binding energy of compound 2, which is -10.14 kcal / mol. According to the predicted activity calculated by the formula, the activity of compound 2 (0.0406 μM) is higher than the activity of compound ML-300 (0.257 μM). Figure 8 .
[0130] Binding energy comparison diagram, see Fig. 9 For comparison of inhibitory activity, see Fig.10 .
[0131] The above description is only a specific implementation mode of the present invention, but the protection scope of the present invention is not limited thereto. Any modifications, equivalent substitutions and improvements made by any technician familiar with the technical field within the technical scope disclosed by the present invention and within the spirit and principle of the present invention should be covered by the protection scope of the present invention.
Claims
1. A marine drug against the new coronavirus, characterized in that: Marine drugs against the new coronavirus are based on the virtual screening method of protein structure molecular docking and molecular dynamics simulation to obtain compound formula 2, molecular formula: C 29 H 39 NO6, molecular weight 497.63 g / mol; Its characteristic structure is:
2. The marine drug against the new coronavirus as claimed in claim 1, characterized in that: The use of marine drugs against the new coronavirus, wherein the compound formula 2 includes a pharmaceutically acceptable carrier.
3. The marine drug against the new coronavirus according to any one of claims 1-2, characterized in that: Application of marine drugs against novel coronavirus, including Middle East Respiratory Syndrome, coronavirus and novel coronavirus patients for treatment.
4. A method for preparing a marine drug against the new coronavirus, characterized in that: The following steps are involved: Screening docking system; Active compounds were collected through the CMNPD database; Molecular docking screening was performed using AutoDock Vina software; Compare the scores of the screened compounds with those of the control group compounds; Conduct molecular dynamics simulations and analyses; Binding energies were calculated and comparative analysis was performed to identify the compound with the best binding energy.
5. The preparation method according to claim 4, characterized in that: The docking system screened includes compounds against the novel coronavirus obtained through virtual screening with the novel coronavirus protein as the target. The specific steps include: Collect and prepare three-dimensional structures of novel coronavirus proteins; The compound library in the CMNPD database was screened by virtual screening to find candidate compounds with high affinity to the novel coronavirus protein; Molecular docking and kinetic simulation analyses were performed on the candidate compounds to evaluate their binding stability and drug potential.
6. The preparation method according to claim 4, characterized in that: The preparation of the marine drug against the new coronavirus further comprises the following steps: Combining the screened compound with a pharmaceutically acceptable carrier to prepare a pharmaceutical preparation for clinical application; To evaluate the stability, bioavailability, and antiviral activity of the drug formulation; Conduct in vivo and in vitro experiments to verify its therapeutic efficacy and safety, and provide data support for clinical application.
Citation Information
Patent Citations
Anti-monkey pox virus novel structure compound composition and application thereof
CN117603293A
Diketopiperazine alkaloid compound for resisting novel coronavirus and application of diketopiperazine alkaloid compound
CN117659052A
